Shanghai Hanhong Scientific Co., Ltd. was established in 2003, with its headquarters located in the National University Science Park of East China University of Science and Technology. It is a high-tech enterprise engaged in the production of drug molecule building blocks, drug intermediates and active pharmaceutical ingredients (APIs), as well as providing CRO and CDMO services. The company's core products include amino acid derivatives, drug molecule building blocks, peptide and peptidomimetic APIs and intermediates. Currently, the company has total assets of 150 million yuan, net assets of over 80 million yuan, and a staff of 150, including 4 PhDs, 12 masters and over 70 undergraduates. In 2022, its sales revenue reached 210 million yuan. The company is a "Specialized, Refined, Unique and Innovative" enterprise in Shanghai and a National High-tech Enterprise.
Hanhong focuses on the biopharmaceutical field and is always committed to independent technological innovation. After years of technological accumulation, it has currently established a synthetic biology technology platform, a chiral chemistry technology platform, and a green chemistry technology platform. It has formed core technological advantages in the field of peptide and peptidomimetic APIs. The company has established R&D centers in Fengxian, Shanghai and Lanzhou, covering a total area of 3,200 square meters, with over 60 R&D personnel. It has also set up production bases in Binhai, Jiangsu, Gaotang, Shandong, and Lanzhou, Gansu, with 8 flexible production lines for drug molecule building blocks and intermediates, and a total of over 300 reactors. Currently, Hanhong can provide customers with catalogued products such as drug molecule building blocks, pharmaceutical intermediates, human APIs, veterinary APIs, food additives, feed additives, and raw materials for health products. Hanhong's non-natural amino acids, protected amino acids, amino acid derivatives series intermediates, and peptide and peptidomimetic APIs have core competitiveness and enjoy a relatively high market share.
In addition to catalog products, Hanhong, relying on its R&D and production capabilities, can also provide CRO and CDMO services for customers from drug research and development to the production stage.
Relying on the company's R&D capabilities and production facilities, and focusing on the drug R&D and drug production industrial chain, with the aim of achieving an outstanding life and establishing a benchmark enterprise, by building a professional growth platform for employees and creating a dual growth engine of innovation and lean management, we are dedicated to providing customers with full-cycle and integrated products and services from the production of drug molecule building blocks, pharmaceutical intermediates to active pharmaceutical ingredients, leading the global market in the biopharmaceutical niche field and realizing the high-quality development dreams of both employees and the enterprise.
